August 26, 2008 -- Biomics Biotechnologies (Nantong) Co., a company focused on RNAi drug R&D, closed a Series B funding of 34 million RMB ($5 million) on July 31 2008. The financing follows the company’s $3.5 million Series A round of January 2007, according to Zero2IPO. The B round was led by Jiangsu Dinghong Venture Capital Co., Ltd., with Jiangsu Benefit Rise Group also participating. More details...
